{"id":"NCT00799266","sponsor":"Novartis Pharmaceuticals","briefTitle":"An Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids","officialTitle":"A Multicenter, Randomized, Double-blind, Placebo Controlled Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly Compared to Placebo in Osteoporotic Children Treated With Glucocorticoids.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-12-04","primaryCompletion":"2018-03-05","completion":"2018-03-05","firstPosted":"2008-11-27","resultsPosted":"2019-07-05","lastUpdate":"2020-09-02"},"enrollment":34,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Osteoporosis"],"interventions":[{"type":"DRUG","name":"Zoledronic acid","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Zoledronic acid","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study was designed to evaluate the efficacy and safety of zoledronic acid compared to placebo in osteoporotic children treated with glucocorticoids","primaryOutcome":{"measure":"Mean Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) Z-score at Month 12","timeFrame":"Month 12","effectByArm":[{"arm":"Zoledronic Acid","deltaMin":0.582,"sd":0.1279},{"arm":"Placebo","deltaMin":0.168,"sd":0.1449}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0392"}]},"eligibility":{"minAge":"5 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":8},"locations":{"siteCount":12,"countries":["Australia","Canada","Hungary","Russia","South Africa","United Kingdom"]},"refs":{"pmids":["34228102"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":18},"commonTop":["Arthralgia","Back pain","Diarrhoea","Nausea","Vomiting"]}}